GH Research's Phase 2b trial of GH001 for treatment-resistant depression met its primary endpoint, showing significant efficacy and a favorable safety profile.
The potential legalization of magic mushrooms is heading to Olympia next week as state lawmakers prepare to hear testimony on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback